Onconetix Inc
ONCO
Company Profile
Business description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Contact
201 East Fifth Street
Suite 1900
CincinnatiOH45202
USAT: +1 513 620-4101
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Earnings winners: BHP, NAB & TLS lead the pack
The winners of this weeks earnings that saw strong investor backing
stocks
Walmart earnings: Growth in digital buoys margin amid consumer trade-down
We think Walmart stock is significantly overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,303.20 | 9.30 | 0.10% |
| CAC 40 | 8,507.97 | 109.19 | 1.30% |
| DAX 40 | 25,260.69 | 217.12 | 0.87% |
| Dow JONES (US) | 49,625.97 | 230.81 | 0.47% |
| FTSE 100 | 10,702.10 | 75.06 | 0.71% |
| HKSE | 26,413.35 | 292.59 | -1.10% |
| NASDAQ | 22,886.07 | 203.34 | 0.90% |
| Nikkei 225 | 56,825.70 | 642.13 | -1.12% |
| NZX 50 Index | 13,308.52 | 135.68 | -1.01% |
| S&P 500 | 6,909.51 | 47.62 | 0.69% |
| S&P/ASX 200 | 9,081.40 | 17.00 | 0.19% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |